



 **SHIONOGI**
Mulpleta®
(lusutrombopag) 3mg tablets



- First TPO (thrombopoietin receptor) agonist approved
- Used to treat **thrombocytopenia**
- Induces the proliferation and differentiation of human bone marrow progenitor cells into megakaryocytes, consistently increasing platelet levels
- Used as alternative to platelet transfusion, claimed to be more effective
- Approved: Japan (2015), USA (2018)

WO2009017098 – decagram scale synthesis



WO2015093586A1 – kilogram scale production

